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Abstract
Antiretroviral therapy (ART) is associated with improved kidney function; however, the
nucleotide reverse transcriptase inhibitor (NRTI) tenofovir disoproxil fumarate (TDF) has been
associated with decreased kidney function and proteinuria.
Methods—We examined changes in urine protein:creatinine (UPCR) and albumin:creatinine
(UACR) ratios in 245 ART-naïve participants in A5202 randomized in a substudy to blinded
NRTI (abacavir/lamivudine, ABC/3TC, n=124 or TDF/emtricitabine, TDF/FTC, n=121) with
open-label protease inhibitor (PI) atazanavir/ritonavir (ATV/r) or non-nucleoside reverse
transcriptase inhibitor (NNRTI) efavirenz (EFV).
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Results—At baseline, 18% of participants had clinically significant proteinuria (UPCR ≥ 200
mg/g) and 11% had clinically significant albuminuria (UACR ≥ 30 mg/g). The prevalence of
clinically significant proteinuria and albuminuria decreased from baseline to week 96 in all
treatment groups. In intention-to-treat analyses, there was a significant effect of NRTI component
on fold-change in UPCR (p=0.011) and UACR (p=0.018) from baseline to week 96, with greater
improvements in participants randomized to ABC/3TC. There was no significant effect of
NNRTI/PI component on fold-change in UPCR (p=0.23) or UACR (p=0.88), and no significant
interactions between NRTI and NNRTI/PI components.
Conclusion—In this pre-specified secondary analysis, ART initiation was associated with
improvements in proteinuria and albuminuria, with significantly greater improvements in
participants randomized to ABC/3TC versus TDF/FTC. These are the first data from a randomized
trial to suggest that initiation of TDF/FTC may not be associated with the same degree of
improvement in proteinuria and albuminuria that have been reported with other regimens. Future
studies should consider the long-term clinical significance of these findings.
Introduction
HIV-infected individuals are at increased risk for chronic kidney disease (CKD), as
indicated by a decrease in estimated glomerular filtration rate (eGFR) or an increase in
urinary protein excretion, and the presence of CKD is associated with both AIDS and non-
AIDS events.1-5 Higher urinary protein excretion, ranging from overt proteinuria to
microalbuminuria, has been associated with increased risk of mortality in HIV-infected
individuals, independent of eGFR.2-5 Although multiple studies have demonstrated
improvements in eGFR or proteinuria with antiretroviral therapy (ART),6-8 in observational
studies cumulative exposure to the nucleotide reverse transcriptase inhibitor (NRTI)
tenofovir disoproxil fumarate (TDF) and the ritonavir-boosted protease inhibitors (PI)
atazanavir/ritonavir (ATV/r) and lopinavir/r have also been associated with low eGFR, and
in the case of TDF, with increases in proteinuria.9-11 Randomized trials comparing TDF/
emtricitabine (TDF/FTC) and abacavir/lamivudine (ABC/3TC) in ART-naïve adults have
not demonstrated a higher risk of developing low eGFR among participants randomized to
initiate ART containing TDF/FTC, and in the ASSERT study, the change in albuminuria
was also similar between treatment arms over 48 weeks of therapy. 121314 We evaluated the
effects of NRTI and NNRTI/PI components on changes in proteinuria and albuminuria over
96 weeks among ART-naïve participants in the metabolic sub-study of a randomized HIV
treatment trial.
Methods
AIDS Clinical Trials Group (AGTG) Study A5202 randomized ART-naïve participants to a
blinded NRTI component (ABC/3TC or TDF/FTC) and to an open-label PI or NNRTI
component (ATV/r or efavirenz, EFV).14 Intention to enroll in the metabolic substudy
A5224s was a stratification factor for randomization in the parent trial. A pre-specified
secondary objective of A5224s was to compare the change in proteinuria and albuminuria in
participants randomized to TDF/FTC versus ABC/3TC, and in participants randomized to
open-label ATV/r versus EFV.15
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ACTG Studies A5202 and A5224s were supported by the National Institutes of Health.
Abbott Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline
provided the study medications. The decision to publish the manuscript was solely that of
the academic authors.
Study Participants
Inclusion criteria for the parent trial A5202 (n=1858) included age ≥ 16 years, HIV-1 RNA
> 1000 copies/mL, and Cockcroft-Gault creatinine clearance > 60 mL/min. The protocol did
not initially exclude participants with hepatitis B virus (HBV) co-infection but was later
amended to exclude participants with a positive HBV surface antigen within six months of
study entry.14 Additional exclusion criteria for the metabolic sub-study A5224s (n=269)
included endocrine disease (diabetes mellitus and Cushing’s syndrome), uncontrolled
thyroid disease or hypogonadism, and use of glucocorticoids, anabolic steroids, growth
hormone, or osteoporosis medications. The institutional review board at each participating
site approved the study protocol, and all participants provided written informed consent. The
study is registered with clinicaltrials.gov, number NCT00118898.
Study Measurements and Definitions
In A5224s, fasting urine and serum samples were collected at study entry (baseline), week
24, week 48, and week 96; additional specimens were collected at 48-week intervals until 96
weeks after the last subject was enrolled in A5202. Urine protein, albumin, and creatinine
were measured centrally at Quest Diagnostics. Urine protein and creatinine were measured
using colorimetric assays (Pyragallol red and Jaffe, respectively), and urine albumin was
measured using an immunoturbidimetric assay for calculation of the urine protein:creatinine
(UPCR) and albumin:creatinine (UACR) ratios; all assays were performed on a Beckman
Coulter/Olympus platform. Clinically significant proteinuria and albuminuria were defined
based on clinical guidelines as a UPCR ≥ 200 mg/g or a UACR ≥ 30 mg/g.16 Dipstick
urinalysis and fasting serum creatinine and glucose were measured locally. For the purposes
of this analysis, the CKD Epidemiology Consortium (CKD-EPI) equation was used to re-
calculate eGFR from serum creatinine, in order to provide a more accurate estimate of this
important potential confounder. The CKD-EPI eGFR equation has demonstrated the best
overall performance in HIV-positive adults, as compared to a gold standard measure of
GFR. 17, 18 Homeostasis model assessment-insulin resistance (HOMA-IR) was calculated
from fasting insulin and glucose. HBV and hepatitis C virus (HCV) co-infections were
defined by positive HBV surface antigen or HCV antibody, respectively.
Statistical Analysis
A pre-specified secondary objective of A5224s was to compare changes in UPCR and
UACR from baseline to week 96 between pooled, randomized NRTI components (TDF/FTC
versus ABC/3TC, with NRTI/PI components combined) and between NNRTI and PI
components (ATV/r versus EFV, with NRTIs combined). Primary analyses were performed
using intent-to-treat principles based on randomized treatment assignment in which all
available data were used and modifications to randomized treatment and missing values
were ignored.
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In February 2008, after a median follow-up of 97 weeks, the Data Safety and Monitoring
Board (DSMB) recommended unblinding the NRTI component for A5202 participants with
screening HIV-RNA ≥ 100,000 copies/mL; participants receiving ABC/3TC were permitted
to modify their regimen.14 To account for changes in therapy, supplemental as-treated
analyses were performed in which values were censored after a change in the randomized
NRTI component (when comparing NRTI components) or NNRTI/PI component (when
comparing NNRTI/PI components). Post hoc sensitivity analyses included only participants
who had achieved virologic suppression (HIV-RNA < 50 copies/mL) at week 96.
Because UPCR and UACR were not normally distributed, data were log10 transformed prior
to analysis. For ease of interpretation, the exponential of the estimated mean change in the
transformed data was used to obtain the estimated mean fold change; a mean fold-change =
1 would correspond to no change in mean UPCR or UACR from baseline, while a mean
fold-change < 1 would correspond to a decrease in mean UPCR or UACR from baseline.
The unadjusted analysis of the effects of NRTI component and NNRTI/PI component on
changes in UPCR or UACR were evaluated separately using two-sample t-tests. Linear
regression was used to initially test for interactions between NRTI and NNRTI/PI
components. P-values below 0.05 (< 0.10 for interactions) were considered statistically
significant. To assess baseline characteristics independently associated with changes in
UPCR or UACR, multivariable linear regression models were constructed using backwards
selection. Baseline characteristics considered for inclusion were age, sex, race/ethnicity,
HIV-1 RNA, CD4 cell count (CD4), eGFR, presence of dipstick proteinuria, systolic and
diastolic blood pressure, HBV or HCV co-infection, HOMA-IR, and body mass index
(BMI). All baseline variables with univariate p-value <0.20 were considered for inclusion in
the models, and variables with a p-value <0.05 were retained; NRTI component and
NNRTI/PI component were retained regardless of p-value. Analyses were performed using
SAS, version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Among 269 participants enrolled in the A5224s substudy, 245 participants with baseline
UPCR and/or UACR contributed data to this analysis. Compared to excluded participants,
included participants tended to be older and were less likely to be white, although these
differences were not significant (p=0.14 and 0.07, respectively). Included and excluded
participants were not significantly different with respect to other baseline characteristics (all
p > 0.3). 181 participants with available data for UPCR and/or UACR at the 96-week visit
were included in the primary intention to treat analyses. These participants had marginally
higher mean body weight and diastolic blood pressure (p=0.066 and 0.052, respectively), but
were not significantly different with respect to baseline characteristics from the 64
participants who did not contribute to the primary analysis (all other p>0.12).
Baseline characteristics of included participants were well balanced across the treatment
groups (Table 1). The mean age of included participants was 39 years, 85% were male, and
35% were of non-Hispanic black race. Only 19% had an eGFR < 90mL/min/1.73m2,
including two participants who met entry criteria based on creatinine clearance > 60mL/min
but who had CKD-EPI eGFR < 60 mL/min/1.73m2. Dipstick proteinuria ≥ trace was
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detected in 29% of participants and was balanced across the treatment groups. The median
UPCR (95 mg/g) and UACR (4.75 mg/g) were within the normal range (<200mg/g and
<30mg/g, respectively).
Effect of NRTI assignment on changes in UPCR and UACR
The effects of treatment assignment on the change in UPCR and UACR are summarized in
Table 2. There were no significant interactions between the NRTI and NNRTI/PI
components (p=0.33 for analysis of change in UPCR, p=0.91 for UACR). In the primary
intention-to-treat analyses, there was significantly greater fold-change in both UPCR and
UACR in those randomized to ABC/3TC versus TDF/FTC (Figure 1, panels A and C). The
mean fold-change in UPCR from baseline to week 96 among 84 participants randomized to
ABC/3TC was 0.80 (95% CI 0.70, 0.91), corresponding to a significant decrease in UPCR
from baseline. Among 83 participants randomized to TDF/FTC, the mean fold-change in
UPCR was 1.02 (95% CI 0.89, 1.17), corresponding to no significant change in UPCR from
baseline to week 96. Overall, there was a 21.7% difference (Δ) in mean fold-change UPCR
with ABC/3TC compared to TDF/FTC (p=0.011), corresponding to a significantly greater
decrease in UPCR from baseline to week 96 in participants randomized to ABC/3TC.
Results were similar in as-treated analysis in which values were censored after a change in
the randomized NRTI component.
In the primary intention-to-treat analysis for UACR, the mean fold-change from baseline to
week 96 among 92 participants randomized to ABC/3TC was 0.69 (95% CI 0.57, 0.84),
corresponding to a significant decrease in UACR from baseline. Among 86 participants
randomized to TDF/FTC, the mean fold-change in UACR was 0.98 (95% CI 0.80, 1.19),
corresponding to no significant change in UACR from baseline to week 96. Overall, there
was a 28.8% difference in mean fold-change UACR with ABC/3TC compared to TDF/FTC
(p=0.018), corresponding to a significantly greater decrease in UACR from baseline to week
96 in participants randomized to ABC/3TC. Results for the change in UACR were similar,
although no longer statistically significant, in as-treated analysis in which values were
censored after a change in the randomized NRTI component.
Although there were no significant interactions between the NRTI and NNRTI/PI
components, pre-specified intention-to-treat analyses of NRTI effect were performed within
each NNRTI/PI arm for descriptive purposes. The results were qualitatively similar to the
results of the primary intention-to-treat analyses, with greater mean fold-changes in UPCR
and UACR in participants randomized to ABC/3TC versus TDF/FTC, regardless of the
NNRTI/PI component (Table 2).
There was no significant difference in mean fold-change UPCR or UACR between
participants with and without virologic suppression (HIV-RNA < 50 copies/mL) at 96 weeks
(data not shown; p>0.8 for both). The proportion of included participants who achieved
virologic suppression did not differ significantly between those randomized to ABC/3TC
(78/93, 83.9%) versus TDF/FTC (79/88, 89.8%; Fisher’s exact p=0.28). In post hoc
sensitivity analyses, we evaluated the effect of treatment assignment on the changes in
UPCR and UACR including only those participants who achieved virologic suppression at
96 weeks. In these analyses, the difference in mean fold-change UPCR was similar in
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magnitude and direction to the primary analysis, but was not statistically significant. The
difference in mean fold-change UACR was marginally significant and similar in magnitude
and direction to the primary analysis.
In a separate intention-to-treat analysis at week 48, the effect of NRTI component on mean
fold-change in UPCR was significant but smaller in magnitude than at week 96 (p=0.043).
The initial decline in UACR from baseline to week 24 appears to be similar in participants
randomized to ABC/3TC versus TDF/FTC (Figure 1, panel C), and there was no statistically
significant effect of NRTI component on the change in UACR at week 48 (p=0.74).
Effect of NNRTI/PI assignment on changes in UPCR and UACR
There were no significant effects of open-label NNRTI/PI component on the change in
UPCR or UACR from baseline to week 96 (Figure 1, panels B and D). The mean fold-
change in UPCR from baseline to week 96 among 79 participants randomized to ATV/r
(0.85, 95% CI 0.74, 0.98) was not significantly different than that observed among 88
participants randomized to EFV (0.96, 95% CI 0.84, 1.09; p=0.23). The mean fold-change in
UACR among 88 participants randomized to ATV/r (0.81, 95% CI 0.66, 0.99) was not
significantly different than that observed among 90 participants randomized to EFV (0.83,
95% CI 0.68, 1.01; p=0.88).
Adjusted analyses
In the multivariable intention-to-treat analyses, there remained a significantly greater fold-
change in UPCR (Table 3) and UACR (Table 4) at week 96 in participants randomized to
ABC/3TC versus TDF/FTC. After adjusting for NRTI and NNRTI/PI components, higher
eGFR and HOMA-IR were associated with a decrease in UPCR from baseline to week 96;
higher baseline CD4 count and absence of dipstick proteinuria were associated with an
increase in UPCR. In the multivariable analysis for change in UACR, screening HIV-RNA ≥
100,000 copies/mL and higher baseline eGFR and HOMA-IR were associated with a
decrease in UACR from baseline to week 96; higher baseline CD4 and absence of dipstick
proteinuria were associated with an increase in UACR. Traditional CKD risk factors,
including older age, black race, and hepatitis co-infection, were not significantly associated
with changes in UPCR or UACR from baseline to week 96.
Effect of treatment assignment in participants with significant proteinuria or albuminuria
At baseline, 18% of included participants had clinically significant proteinuria (UPCR ≥ 200
mg/g) and 11% had clinically significant albuminuria (UACR ≥ 30 mg/g) (Table 1). Only
four participants had a baseline UPCR ≥ 1 g/g, consistent with overt proteinuria of more
than 1 g/24 hours. These four participants and one additional participant had a baseline
UACR ≥ 300 mg/g, signifying macroalbuminuria; by chance, all five of these participants
with overt proteinuria and/or macroalbuminuria were randomized to open-label ATV/r.
Overall, there was a decrease in the prevalence of clinically relevant proteinuria and
albuminuria from baseline to week 96 in all treatment groups. Among participants with data
available at baseline and at week 96, the prevalence of UPCR ≥ 200 mg/g decreased from
18.0% to 9.6%, and the prevalence of UACR ≥ 30 mg/g decreased from 11.2% to 5.1%
(Exact McNemar’s test p=0.013 for both comparisons).
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In 21 of 30 participants with baseline UPCR ≥ 200mg/g, the week 96 UPCR was < 200
mg/g. These 21 cases were balanced across the 4 treatment arms. New onset proteinuria ≥
200 mg/g was observed in 7 of 137 participants with baseline UPCR < 200 mg/g. Five of
these participants were randomized to TDF/FTC (2 with EFV and 3 with ATV/r) and 2 were
randomized to ABC/3TC (one in each NNRTI/PI arm). In 14 of 20 participants with
baseline UACR ≥ 30 mg/g, the week 96 UACR was normal. Five of these participants were
randomized to TDF/FTC (4 with EFV and 1 with ATV/r) and 9 were randomized to
ABC/3TC (3 with EFV and 6 with ATV/r). New onset albuminuria ≥ 30 mg/g was observed
in 3 of 158 participants with normal baseline UACR, all of whom were randomized to
TDF/FTC (2 with EFV and 1 with ATV/r). The numbers of participants with clinically
significant proteinuria and albuminuria were too small to allow statistical comparisons.
Discussion
In this pre-specified secondary analysis of the metabolic substudy of a randomized clinical
trial, we observed significantly greater improvements in proteinuria and albuminuria over 96
weeks among ART-naïve adults randomized to ART containing ABC/3TC versus TDF/
FTC. This effect remained significant after adjusting for potential imbalances in
randomization. Assignment to open-label ATV/r versus EFV was not associated with a
significant difference in proteinuria or albuminuria over 96 weeks of treatment.
These results are consistent with previous clinical trials demonstrating improvements in
markers of CKD with the initiation of ART,6-8 even with regimens that include TDF, and it
is reassuring that the prevalence of clinically significant proteinuria and albuminuria
decreased in all treatment arms. Although observational studies have demonstrated an
association between cumulative exposure to TDF and increased incidence of proteinuria,10
the change in albuminuria over 48 weeks did not differ significantly between participants
randomized to TDF/FTC versus ABC/3TC in the ASSERT study. 13 While we did not
observe an increase in the prevalence or level of proteinuria or albuminuria over 96 weeks of
therapy with TDF/FTC, the pattern of change in UACR suggests that an early improvement
with ART initiation was followed by a rebound in albuminuria with longer exposure to
TDF/FTC (Figure 1, panel C). This result is consistent with the previously reported
association between cumulative exposure to TDF and increased incidence of proteinuria as
assessed by dipstick urinalysis, which largely detects albuminuria.10 While it is possible that
our results reflect an initial improvement in HIV-related kidney injury with virologic
suppression, followed by the development of proximal tubular injury or dysfunction in the
setting of TDF/FTC, the current study was not designed to evaluate potential mechanisms.
Similarly, we cannot explain the apparent differences in pattern and magnitude of change in
proteinuria and albuminuria, which may indicate different types of kidney injury. Future
studies should include additional biomarkers that can help to distinguish between HIV-
related and ART-related kidney injury. Finally, it is notable that clinically significant
proteinuria and albuminuria were observed in fewer than 20% of participants at baseline.
Nonetheless, even small elevations in proteinuria and albuminuria, such as those observed in
this study, have been associated with clinically significant differences in cardiovascular
disease and all-cause mortality.2-5
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While recent studies have suggested that cumulative exposure to ATV/r is associated with
decreased eGFR,9-11 we did not observe a differential effect of ATV/r versus EFV on
changes in proteinuria or albuminuria, other indicators of CKD. It is possible that this lack
of difference reflects a deleterious effect of EFV, consistent with a previously reported
association between NNRTI use and higher albuminuria.19 Of note, by chance all subjects
with high levels of proteinuria and albuminuria were randomized to the ATV/r arm. We
have previously reported greater improvements in albuminuria in individuals with higher
baseline levels.20 It is possible that imbalance in baseline proteinuria and albuminuria could
have masked a true benefit of EFV over ATV/r. Nonetheless, the number of participants
with high levels of proteinuria or albuminuria was small, and the effect of outliers should be
minimized by the log transformation of UPCR and UACR data. Of note, the distribution of
proteinuria and albuminuria was similar between the NRTI treatment arms, the primary
focus of this analysis.
Although this is the first study to demonstrate differential effects of TDF/FTC and
ABC/3TC on proteinuria and albuminuria using data from a randomized trial, several
additional limitations should be acknowledged. First, although UPCR and UACR
measurements were centralized, our analysis was based on a single measurement of
proteinuria and albuminuria at each time-point. It is reassuring that the observed effects of
NRTI component were in the same direction, albeit less significant, at 48 weeks. Second, the
study was not specifically powered for this secondary analysis, and missing data at week 96
further limited our sample size for the primary intention-to-treat analyses. Although there
were no statistically significant differences with respect to baseline characteristics, it is also
possible that participants with missing data at week 96 differed from participants who were
included in the primary analysis. Third, our analysis was complicated by the unblinding of
the NRTI component and switches from ABC/3TC to TDF/FTC in participants with high
screening HIV-RNA following the DSMB report in February 2008. Results of the as-treated
analyses with data censored after a change in NRTI were qualitatively similar, although the
differences in albuminuria reduction were no longer statistically significant. Fourth, while it
is reassuring that proteinuria and albuminuria did not worsen in participants randomized to
TDF/FTC, our results are short term when viewed in the context of lifelong ART. By
design, follow-up of study participants ended when the last enrolled participant reached
week 96; as a result there is a decreasing sample size on visits after this time point.
Particularly given the low baseline prevalence of clinically significant proteinuria/
albuminuria or decreased eGFR, these short-term results do not exclude the possibility of
worsening proteinuria or albuminuria with more prolonged exposure. We did observe a
more significant effect of NRTI assignment at week 96 than at week 48, which could
suggest a cumulative effect of treatment; unfortunately the small sample size after week 96
did not allow us to explore this further. Fifth, although we did not detect a significant
interaction between NRTI and NNRTI/PI component, the current analysis likely only had
adequate power to detect large treatment interactions. Finally, our results may not be
generalizable to patients with baseline creatinine clearance <60 mL/min or with uncontrolled
diabetes, who were excluded from the current study and who are at greatest risk for adverse
renal and cardiovascular outcomes. In contrast, more than one-third of participants were of
self-reported black race, another important risk factor for CKD. There were no significant
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interactions between NRTI component and race, age, or blood pressure, suggesting that the
observed NRTI effects were not significantly influenced by these traditional CKD risk
factors.
Our data are consistent with previous studies demonstrating improvements in proteinuria or
albuminuria following the initiation of ART.6-8 These are the first data from a randomized
clinical trial to suggest that the initiation of TDF/FTC in ART-naïve individuals may not be
associated with the same degree of improvements in proteinuria and albuminuria that are
observed with ABC/3TC. Future studies should consider the long-term clinical significance
of these differences, particularly among individuals with pre-existing CKD or CKD risk
factors.
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Figure 1.
Mean fold-change (95% confidence interval) in urine protein:creatinine ratio (panels A and
B) and urine albumin: creatinine ratio (panels C and D) among 245 participants randomized
to initiate antiretroviral therapy in A5224s. Mean fold-change in each ratio is compared
between participants randomized to abacavir/ lamivudine versus TDF/ emtricitabine (A and
C) and between participants randomized to open-label EFV versus ATV/ ritonavir (B and
D). Data are presented through week 192 for descriptive purposes; comparative statistics
were performed at week 48 and week 96. *two-sample t-test.
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